On April 21, 2020 Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women’s health and prostate cancer, reported it will hold a webcast and conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on Wednesday, April 22, 2020, to discuss results from the Phase 3 SPIRIT 2 study of once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis (Press release, Myovant Sciences, APR 21, 2020, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-host-webcast-and-conference-call-830-am-2 [SID1234556503]). The company will also discuss results from a separate ovulation inhibition study with relugolix combination therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast/Teleconference Details
To participate in the live conference call, please dial 1-800-532-3746 for domestic callers and +1-470-495-9166 for international callers. A live webcast of the conference call will also be available on the investor relations page of Myovant’s website at investors.myovant.com and will remain archived on Myovant’s website for at least 30 days.